Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Immunology
• Genetics

Background:

• Microglia activation is a key feature in neurodegenerative diseases like amyotrophic lateral sclerosis (ALS).
• The precise role of microglia activation in ALS pathogenesis remains unclear, with debate on whether it's a cause or consequence.
• Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of motor neurons.

Purpose of the Study:

• To investigate the therapeutic potential of interleukin-4 (IL-4) gene therapy in modulating microglia behavior for ALS treatment.
• To determine if inducing an embryonic-like microglia phenotype can enhance motor neuron survival in an ALS mouse model.

Main Methods:

• Central nervous system (CNS) delivery of IL-4 using a lentiviral-mediated gene therapy approach.
• Transcriptome analysis to characterize the phenotype of IL-4-treated microglia.
• Assessment of clinical outcomes and motor neuron survival in SOD1^G93A mice treated with IL-4 gene therapy.

Main Results:

• IL-4 gene therapy induced microglia proliferation and adoption of a slowly proliferating, embryonic-like phenotype.
• IL-4 treatment led to a general amelioration of clinical outcomes in the early stages of ALS in SOD1^G93A mice.
• The therapeutic benefits were limited to the early, slowly progressive phase, with no reversal of neurodegeneration in the late, fast-progressing phase.

Conclusions:

• Modulating microglia phenotype with IL-4 gene therapy shows promise for early-stage ALS intervention.
• The approach effectively promotes motor neuron survival during the initial disease phase.
• Further strategies are needed to address neurodegeneration in advanced stages of ALS.